nantkwest

NATURAL KILLER CELLS: THE QUEST TOWARDS A CURE

Living Drugs in a Bag® therapy

OUR WAR AGAINST CANCER

Harnessing Nature’s Immune System
COVID-19 updates:
Learn how NantKwest is responding to Coronavirus as well as additional information & resources.

The World’s First Off The Shelf Genetically

Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

haNK

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

taNK

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting
t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

t-haNK
previous arrow
next arrow
Slider

The World’s First Off The Shelf Genetically Engineered Natural Killer Cell Platform

Meet our NK Cells

haNK®

Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high binding affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

taNK®

Chimeric Antigen Receptor directed killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

t-haNK™

Our newest line of investigational products are an innovative combination of our haNK and taNK platforms in a single genetic engineered platform that incorporates all the features of our haNK platform together with a CAR with the resulting t-haNK designed to avail itself of all three modes of killing: innate, antibody mediated and Chimeric Antigen Receptor (CAR) directed killing.

Recent News

NantKwest Announces Pricing of Public Offering of Common Stock

EL SEGUNDO, Calif.--Jun. 25, 2020-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offering of an aggregate of 7,410,000 shares of its common stock (3,700,000 shares...